Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tyramine Safety Sub-study in Rasagiline-Treated Parkinson's Patients
NCT00203125Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2000
- Primary completion
- Jan 2003
- Modality
- Irreversible Covalent Inhibitors
01
Overview
Phase 3, randomised, double-blind trial of rasagiline in Parkinson's disease (PD) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Increase in systolic blood pressure of > 30mmHg from baseline at 26 weeks and Bradycardia with heart rate below 40 beats per minute at 26 weeks. Started Oct 2000; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00203125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203125.